0
Obstructive Lung Diseases |

Analysis of Improvement in SGRQ Component Scores With QVA149: Pooled Data From the FLIGHT1 and FLIGHT2 Studies

Paul Jones, MD; Michael Larbig, MD; Samopriyo Maitra; Angel FowlerTaylor, MD; Donald Banerji, MD
Author and Funding Information

St George's, University of London, London, United Kingdom; Novartis Pharma AG, Basel, Switzerland; Novartis Healthcare Pvt Ltd, Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ


Chest. 2015;148(4_MeetingAbstracts):722A. doi:10.1378/chest.2251187
Text Size: A A A
Published online

Abstract

SESSION TITLE: COPD Posters IV

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: The SGRQ is a well-recognized tool for evaluation of quality of life in patients with COPD. The questionnaire consists of three components, symptoms, activity and impact. QVA149 110/50 µg, once daily, is a fixed-dose combination of long-acting β2-agonist, indacaterol (IND) and long-acting muscarinic antagonist, glycopyrronium (GLY), approved in over 50 countries including EU, Japan, Canada, Mexico, Australia and Switzerland for maintenance treatment of patients with COPD. The FLIGHT1 and FLIGHT2 studies evaluated the improvement in SGRQ total score with twice daily QVA149 (IND/GLY 27.5/12.5 µg), versus its monocomponents and placebo. Here, we report the results of pooled analysis in terms of improvement in the SGRQ component scores with IND/GLY compared with IND, GLY and placebo.

METHODS: The FLIGHT1 and FLIGHT2 studies were multi-center, double-blind, placebo- and active-controlled, parallel-group studies that randomized patients with moderate to severe COPD to IND/GLY 27.5/12.5 µg, IND 27.5 µg, GLY 12.5 µg or placebo (all twice daily) to assess the efficacy and safety of IND/GLY versus its monocomponents and placebo.

RESULTS: Overall, 2038 patients were included in the pooled analysis (IND/GLY, n=508; IND, n=511; GLY, n=511; placebo, n=508). IND/GLY showed statistically significant improvement in SGRQ total score change from baseline versus IND (least squares mean treatment difference [LSMTD]: -1.7), GLY (LSMTD: -1.5) and placebo (LSMTD: -5.0) at Week 12. Compared with placebo, IND/GLY demonstrated a statistically significant (p<0.001) improvement in all SGRQ component scores. Additionally, improvement in symptom component score was statistically significant (p<0.001) with IND/GLY versus IND and GLY (LSMTD: -3.5 and -3.7, respectively). IND/GLY showed statistically significant improvement in impact component score versus GLY (LSMTD: -1.7, p<0.05). Improvement in activity component score was comparable between IND/GLY and its monocomponents.

CONCLUSIONS: In patients with moderate to severe COPD, IND/GLY showed statistically significant improvements in all the SGRQ component scores compared with placebo.

CLINICAL IMPLICATIONS: IND/GLY can be considered as an alternative treatment which can improve the health status of the patients with moderate to severe COPD.

DISCLOSURE: Paul Jones: Consultant fee, speaker bureau, advisory committee, etc.: Received lecture and consultant fees from Novartis Michael Larbig: Employee: Employee of the study sponsor, Novartis and no other conflicts Samopriyo Maitra: Employee: Employee of the study sponsor, Novartis and no other conflicts Angel FowlerTaylor: Employee: Employee of the study sponsor, Novartis and no other conflicts Donald Banerji: Employee: Employee of the study sponsor, Novartis and no other conflicts

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543